Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol

NCT01023516 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01023516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01023516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
August 31, 2010
Enrollment
615 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)